Literature DB >> 1837503

Dopamine, the dopamine D2 receptor and pituitary tumours.

D F Wood1, J M Johnston, D G Johnston.   

Abstract

Dopamine plays an important role in the hypothalamic-pituitary axis where its major effects are to inhibit pituitary hormone secretion and cell division. Chronic dopamine deficiency has been postulated as a cause of pituitary tumour formation and several lines of evidence exist to suggest that a functional deficiency may develop as a result of defective dopamine receptor action. The available data suggest that a number of sites in the dopamine-D2 receptor-second messenger pathways may be implicated. These abnormalities are reflected in the variety of responses to dopamine and its agonists which have been observed in pituitary tumours both in the clinical situation and in cultured cells in vitro. Whilst it seems likely that the primary defect in pituitary tumour formation lies within the pituitary itself, the role of hypothalamic factors in facilitating tumour growth remains to be explored. Further studies of the dopamine receptor and its function will be of value not only in pathophysiological studies of human pituitary adenomas, but also in the development of new pharmacological agents to treat patients with these tumours.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837503     DOI: 10.1111/j.1365-2265.1991.tb00928.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Growth factors in the pathogenesis of prolactin-secreting tumors.

Authors:  C Missale; P F Spano
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 3.  Medical management of thyrotropin-secreting pituitary adenomas.

Authors:  Paolo Beck-Peccoz; Luca Persani
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Promotion of initial anti-tumor effect via polydopamine modified doxorubicin-loaded electrospun fibrous membranes.

Authors:  Ziming Yuan; Xin Zhao; Xiaohu Wang; Wangwang Qiu; Xinliang Chen; Qi Zheng; Wenguo Cui
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Should dopamine be the first line inotrope in the treatment of neonatal hypotension? Review of the evidence.

Authors:  Sadaf I Bhayat; Harsha M S Gowda; Michael Eisenhut
Journal:  World J Clin Pediatr       Date:  2016-05-08

6.  Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.

Authors:  W Pirker; T Brücke; M Riedl; M Clodi; A Luger; S Asenbaum; I Podreka; L Deecke
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

8.  Nerve growth factor suppresses the transforming phenotype of human prolactinomas.

Authors:  C Missale; F Boroni; M Losa; M Giovanelli; A Zanellato; R Dal Toso; A Balsari; P Spano
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.

Authors:  N P Verhoeff; F J Bemelman; W M Wiersinga; E A van Royen
Journal:  Eur J Nucl Med       Date:  1993-06

Review 10.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.